| Health / Medical Topics |
gp100 Peptide-sensitized Autologous T-cells (CD4+ and CD8+)
A population of CD4+ and CD8+ T-cells isolated from a cancer patient that have been sensitized in vitro to the melanoma-associated antigen gp100. Infusion of gp100 peptide-sensitized autologous T-cells into the cancer patient may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against gp100-positive tumor cells, thereby decreasing tumor growth. (NCI Thesaurus)
YOU MAY ALSO LIKE
A vaccine consisting of synthetic glycoprotein 100 (gp100) melanoma antigen and incomplete Freund's adjuvant (IFA), an emulsifying agent and immune system stimulant,…
A synthetic agent derived from the tumor-associated differentiation antigen gp100 DNA. Gp100 DNA is coated onto microscopic gold beads and used…
A melanoma-associated antigen. When administered in a vaccine formulation, gp100 antigen may stimulate a cytotoxic T cell HLA-A2.1-restricted immune response against…
A vaccine consisting of microscopic gold particles coated with plasmid DNA encoding the glycoprotein 100 (gp100) melanoma antigen and granulocyte-macrophage colony-stimulating factor…
A vaccine consisting of a replication-defective recombinant adenovirus that encodes the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. Vaccination with…
A tumor-specific antigen used in the development of cancer vaccines. Also called glycoprotein 100.
